Loading...
01/11 11:30
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance with a 21% revenue increase, positive gross margins for key products, and raised revenue guidance. Despite increased free cash flow burn, the company shows improved ASPs and volume growth, particularly in Oncology and Biopharma. The Q&A highlights optimism about growth opportunities and strategic partnerships. While there are some concerns about cash burn and management's vague responses on market share, the overall sentiment is positive, supported by strong guidance and strategic initiatives. Given the market cap, a positive stock price movement of 2% to 8% is expected.
Total Revenue $203,500,000 (21% increase year-over-year) driven by strong performance in Oncology and Biopharma.
Oncology Revenue $150,600,000 (20% increase year-over-year) with volume growth of 25% to approximately 59,000 tests, primarily from Guardant360 and Reveal.
Guardant360 ASP $3,000 to $3,100 (increase from approximately $3,000 in Q4 2024) due to improved reimbursement from Medicare Advantage and commercial payers.
Biopharma Revenue $45,400,000 (21% increase year-over-year) driven by partnerships and increased volume leveraging methylation analysis.
Screening Revenue (Shield) $5,700,000 from approximately 9,000 tests, with positive momentum and strong reception from physicians and patients.
Licensing and Other Revenue $1,900,000 (decrease from $5,200,000 in the prior year period) due to lower activity in this segment.
Gross Margin for Reveal Positive gross margin achieved for the first time, driven by a 50% reduction in cost per test.
Gross Margin for Shield Positive gross margin achieved, driven by cost reductions and increased volume.
Non-GAAP Gross Margin 65% (up from 63% in Q1 2024) due to improved ASPs and significant reductions in COGS for Reveal and Shield.
Non-GAAP Operating Expenses $199,600,000 (13% increase year-over-year) in line with expectations, with flat R&D and G&A expenses.
Adjusted EBITDA Loss $58,500,000 (improvement of $2,600,000 compared to a loss of $61,100,000 in Q1 2024).
Free Cash Flow Burn $67,000,000 (increase from $37,000,000 in the prior year period) due to timing of annual bonus payout.
Cash Position Approximately $84,000,000 in cash, cash equivalents, and restricted cash.
2025 Revenue Guidance $880,000,000 to $890,000,000 (19% to 20% growth compared to 2024) raised by $30,000,000 due to stronger than expected volumes and ASPs.
2025 Shield Revenue Guidance $40,000,000 to $45,000,000 (increase from prior guidance of $25,000,000 to $30,000,000) due to ADLT status and higher volume expectations.
2025 Free Cash Flow Burn Guidance $225,000,000 to $235,000,000 (improvement compared to 2024) with a focus on reducing cash burn.
Guardant Reveal: Guardant Reveal has seen strong uptake in breast cancer, with a recent publication showing 83% sensitivity for distant recurrence and 99.5% specificity.
Guardant360 Tissue: Launched upgraded Guardant360 Tissue, a broad multi-omic tissue CGP test, which requires 40% less tissue than competitors.
Shield: Shield testing revenue reached $5,700,000 in Q1, with positive reception from physicians and patients.
Oncology Revenue Growth: Oncology revenue grew 20% year over year to $151,000,000, with volumes increasing 25% to approximately 59,000 tests.
ADLT Status for Shield: Shield received ADLT status, increasing Medicare price from $920 to $1,495, enhancing market positioning.
Gross Margin Improvement: Both Reveal and Shield became gross margin positive in Q1 2025, with Reveal achieving over 50% cost reduction.
Sales Force Expansion: Guardant plans to increase its sales force to 700 reps, enhancing market penetration.
Collaboration with Pfizer: Announced a strategic collaboration with Pfizer, strengthening long-term partnership and expanding market reach.
NCI Vanguard Study Inclusion: Shield selected for inclusion in the National Cancer Institute Vanguard study, validating its multi-cancer detection capabilities.
Regulatory Issues: The company is closely monitoring tariff news, although they do not source any assay inputs directly from China, indicating minimal expected impact from tariffs.
Competitive Pressures: Guardant Health is experiencing strong growth in its oncology business, particularly with Guardant360 and Reveal, but faces competition in the market for liquid and tissue biopsies.
Supply Chain Challenges: The company has completed a thorough materials analysis with third-party vendors to mitigate potential supply chain risks.
Economic Factors: The company expects to reach cash flow breakeven in 2028, with cumulative free cash outflow projected between $450 million to $550 million over the next three years.
Market Adoption Risks: The company is investing in commercial infrastructure to support the Shield test, which is expected to drive growth, but the timing of sales rep productivity ramp-up may affect volume guidance.
Cash Burn: The company reported a free cash flow burn of $67 million in Q1 2025, which is an increase from the previous year, primarily due to the timing of annual bonus payouts.
Oncology Revenue Growth: Oncology revenue grew 20% year over year to $151 million in Q1 2025, with volumes increasing 25% year over year to approximately 59,000 tests.
Guardant360 ASP Improvement: Guardant360 ASP improved to the range of $3,000 to $3,100 due to better Medicare Advantage and commercial reimbursement.
Shield Revenue Guidance: Full year 2025 Shield revenue guidance raised to $40 million to $45 million from $25 million to $30 million, driven by ADLT status and increased volume expectations.
Gross Margin Positive for Reveal and Shield: Both Reveal and Shield became gross margin positive in Q1 2025, with Reveal achieving a cost reduction of over 50% per test.
Strategic Collaboration with Pfizer: Announced a multi-year strategic collaboration with Pfizer, enhancing long-term partnership and biopharma revenue.
Expansion of Commercial Infrastructure: Plans to reinvest incremental screening gross profit back into the business to accelerate commercial infrastructure build-out.
2025 Revenue Guidance: Full year 2025 revenue expected to be in the range of $880 million to $890 million, representing growth of approximately 19% to 20% compared to 2024.
Oncology Revenue Growth Expectation: Oncology revenue expected to grow approximately 18% year over year in 2025, up from prior guidance of 15%.
Free Cash Flow Burn: Expected free cash flow burn for 2025 to be in the range of $225 million to $235 million, an improvement compared to 2024.
Cash Flow Breakeven: Expect to reach cash flow breakeven in 2028 with cumulative free cash outflow of $450 million to $550 million over the next three years.
Shareholder Return Plan: Guardant Health announced a significant increase in its revenue guidance for the Shield program, raising expectations to $40 million to $45 million for 2025, up from a previous estimate of $25 million to $30 million. This increase is attributed to the recent ADLT status for Shield, which raised the average selling price (ASP) to approximately $800 per test starting April 1, 2025. Additionally, the company expects to conduct 52,000 to 58,000 tests, an increase from the prior guidance of 45,000 to 50,000 tests. The gross margin for both Reveal and Shield became positive in Q1 2025, indicating improved profitability for these products.
Share Buyback Program: None
The earnings call summary and Q&A indicate strong revenue growth and optimistic guidance, particularly in oncology and Shield revenues. Despite some uncertainties in FDA timelines and 2026 growth, the positive reception of MCD and Guardant360's growth drivers, along with raised revenue guidance and improved margins, suggest a positive outlook. The market cap indicates a moderate reaction, leading to a 'Positive' sentiment prediction for the stock price over the next two weeks.
The earnings call summary reveals strong financial performance with significant improvements in gross profit and reduced cash flow burn. The strategic collaboration with Pfizer and raised revenue guidance are positive indicators. The Q&A section highlights growth in key products and strong market positioning, despite some uncertainties around Shield V2 data and payer coverage. The market cap suggests moderate volatility, leading to a positive prediction for the stock price movement over the next two weeks.
Despite positive revenue growth and improved gross margins, the company's increasing cash burn and lack of a share buyback program raise concerns. The Q&A section shows optimism about product development and market expansion, but management's unclear responses about market share and trial timelines add uncertainty. Given the company's market cap, the stock price is likely to remain stable, resulting in a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
